Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AZD0171 |
| Trade Name | |
| Synonyms | AZD 0171|AZD-0171 |
| Drug Descriptions |
AZD0171 is a monoclonal antibody that targets leukemic inhibitory factor (LIF), leading to decreased downstream signaling, potentially resulting in antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 1293). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AZD0171 | AZD0171 | 0 | 0 |
| AZD0171 + Carboplatin + Paclitaxel | AZD0171 Carboplatin Paclitaxel | 0 | 0 |
| AZD0171 + Durvalumab | AZD0171 Durvalumab | 0 | 1 |
| AZD0171 + Durvalumab + Gemcitabine + Nab-paclitaxel | AZD0171 Durvalumab Gemcitabine Nab-paclitaxel | 0 | 1 |